Cargando…

Five-Year Outcome After Continuous Flow LVAD With Full-Magnetic (HeartMate 3) Versus Hybrid Levitation System (HeartWare): A Propensity-Score Matched Study From an All-Comers Multicentre Registry

Despite the withdrawal of the HeartWare Ventricular Assist Device (HVAD), hundreds of patients are still supported with this continuous-flow pump, and the long-term management of these patients is still under debate. This study aims to analyse 5 years survival and freedom from major adverse events i...

Descripción completa

Detalles Bibliográficos
Autores principales: Francica, Alessandra, Loforte, Antonio, Attisani, Matteo, Maiani, Massimo, Iacovoni, Attilio, Nisi, Teodora, Comisso, Marina, Terzi, Amedeo, De Bonis, Michele, Vendramin, Igor, Boffini, Massimo, Musumeci, Francesco, Luciani, Giovanni Battista, Rinaldi, Mauro, Pacini, Davide, Onorati, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505657/
https://www.ncbi.nlm.nih.gov/pubmed/37727385
http://dx.doi.org/10.3389/ti.2023.11675
_version_ 1785106949087428608
author Francica, Alessandra
Loforte, Antonio
Attisani, Matteo
Maiani, Massimo
Iacovoni, Attilio
Nisi, Teodora
Comisso, Marina
Terzi, Amedeo
De Bonis, Michele
Vendramin, Igor
Boffini, Massimo
Musumeci, Francesco
Luciani, Giovanni Battista
Rinaldi, Mauro
Pacini, Davide
Onorati, Francesco
author_facet Francica, Alessandra
Loforte, Antonio
Attisani, Matteo
Maiani, Massimo
Iacovoni, Attilio
Nisi, Teodora
Comisso, Marina
Terzi, Amedeo
De Bonis, Michele
Vendramin, Igor
Boffini, Massimo
Musumeci, Francesco
Luciani, Giovanni Battista
Rinaldi, Mauro
Pacini, Davide
Onorati, Francesco
author_sort Francica, Alessandra
collection PubMed
description Despite the withdrawal of the HeartWare Ventricular Assist Device (HVAD), hundreds of patients are still supported with this continuous-flow pump, and the long-term management of these patients is still under debate. This study aims to analyse 5 years survival and freedom from major adverse events in patients supported by HVAD and HeartMate3 (HM3). From 2010 to 2022, the MIRAMACS Italian Registry enrolled all-comer patients receiving a LVAD support at seven Cardiac Surgery Centres. Out of 447 LVAD implantation, 214 (47.9%) received HM3 and 233 (52.1%) received HVAD. Cox-regression analysis adjusted for major confounders showed an increased risk for mortality (HR 1.5 [1.2–1.9]; p = 0.031), for both ischemic stroke (HR 2.08 [1.06–4.08]; p = 0.033) and haemorrhagic stroke (HR 2.6 [1.3–4.9]; p = 0.005), and for pump thrombosis (HR 25.7 [3.5–188.9]; p < 0.001) in HVAD patients. The propensity-score matching analysis (130 pairs of HVAD vs. HM3) confirmed a significantly lower 5 years survival (41.7% vs. 64.1%; p 0.02), freedom from haemorrhagic stroke (90.5% vs. 70.1%; p < 0.001) and from pump thrombosis (98.5% vs. 74.7%; p < 0.001) in HVAD cohort. Although similar perioperative outcome, patients implanted with HVAD developed a higher risk for mortality, haemorrhagic stroke and thrombosis during 5 years of follow-up compared to HM3 patients.
format Online
Article
Text
id pubmed-10505657
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105056572023-09-19 Five-Year Outcome After Continuous Flow LVAD With Full-Magnetic (HeartMate 3) Versus Hybrid Levitation System (HeartWare): A Propensity-Score Matched Study From an All-Comers Multicentre Registry Francica, Alessandra Loforte, Antonio Attisani, Matteo Maiani, Massimo Iacovoni, Attilio Nisi, Teodora Comisso, Marina Terzi, Amedeo De Bonis, Michele Vendramin, Igor Boffini, Massimo Musumeci, Francesco Luciani, Giovanni Battista Rinaldi, Mauro Pacini, Davide Onorati, Francesco Transpl Int Health Archive Despite the withdrawal of the HeartWare Ventricular Assist Device (HVAD), hundreds of patients are still supported with this continuous-flow pump, and the long-term management of these patients is still under debate. This study aims to analyse 5 years survival and freedom from major adverse events in patients supported by HVAD and HeartMate3 (HM3). From 2010 to 2022, the MIRAMACS Italian Registry enrolled all-comer patients receiving a LVAD support at seven Cardiac Surgery Centres. Out of 447 LVAD implantation, 214 (47.9%) received HM3 and 233 (52.1%) received HVAD. Cox-regression analysis adjusted for major confounders showed an increased risk for mortality (HR 1.5 [1.2–1.9]; p = 0.031), for both ischemic stroke (HR 2.08 [1.06–4.08]; p = 0.033) and haemorrhagic stroke (HR 2.6 [1.3–4.9]; p = 0.005), and for pump thrombosis (HR 25.7 [3.5–188.9]; p < 0.001) in HVAD patients. The propensity-score matching analysis (130 pairs of HVAD vs. HM3) confirmed a significantly lower 5 years survival (41.7% vs. 64.1%; p 0.02), freedom from haemorrhagic stroke (90.5% vs. 70.1%; p < 0.001) and from pump thrombosis (98.5% vs. 74.7%; p < 0.001) in HVAD cohort. Although similar perioperative outcome, patients implanted with HVAD developed a higher risk for mortality, haemorrhagic stroke and thrombosis during 5 years of follow-up compared to HM3 patients. Frontiers Media S.A. 2023-09-04 /pmc/articles/PMC10505657/ /pubmed/37727385 http://dx.doi.org/10.3389/ti.2023.11675 Text en Copyright © 2023 Francica, Loforte, Attisani, Maiani, Iacovoni, Nisi, Comisso, Terzi, De Bonis, Vendramin, Boffini, Musumeci, Luciani, Rinaldi, Pacini and Onorati. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Health Archive
Francica, Alessandra
Loforte, Antonio
Attisani, Matteo
Maiani, Massimo
Iacovoni, Attilio
Nisi, Teodora
Comisso, Marina
Terzi, Amedeo
De Bonis, Michele
Vendramin, Igor
Boffini, Massimo
Musumeci, Francesco
Luciani, Giovanni Battista
Rinaldi, Mauro
Pacini, Davide
Onorati, Francesco
Five-Year Outcome After Continuous Flow LVAD With Full-Magnetic (HeartMate 3) Versus Hybrid Levitation System (HeartWare): A Propensity-Score Matched Study From an All-Comers Multicentre Registry
title Five-Year Outcome After Continuous Flow LVAD With Full-Magnetic (HeartMate 3) Versus Hybrid Levitation System (HeartWare): A Propensity-Score Matched Study From an All-Comers Multicentre Registry
title_full Five-Year Outcome After Continuous Flow LVAD With Full-Magnetic (HeartMate 3) Versus Hybrid Levitation System (HeartWare): A Propensity-Score Matched Study From an All-Comers Multicentre Registry
title_fullStr Five-Year Outcome After Continuous Flow LVAD With Full-Magnetic (HeartMate 3) Versus Hybrid Levitation System (HeartWare): A Propensity-Score Matched Study From an All-Comers Multicentre Registry
title_full_unstemmed Five-Year Outcome After Continuous Flow LVAD With Full-Magnetic (HeartMate 3) Versus Hybrid Levitation System (HeartWare): A Propensity-Score Matched Study From an All-Comers Multicentre Registry
title_short Five-Year Outcome After Continuous Flow LVAD With Full-Magnetic (HeartMate 3) Versus Hybrid Levitation System (HeartWare): A Propensity-Score Matched Study From an All-Comers Multicentre Registry
title_sort five-year outcome after continuous flow lvad with full-magnetic (heartmate 3) versus hybrid levitation system (heartware): a propensity-score matched study from an all-comers multicentre registry
topic Health Archive
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505657/
https://www.ncbi.nlm.nih.gov/pubmed/37727385
http://dx.doi.org/10.3389/ti.2023.11675
work_keys_str_mv AT francicaalessandra fiveyearoutcomeaftercontinuousflowlvadwithfullmagneticheartmate3versushybridlevitationsystemheartwareapropensityscorematchedstudyfromanallcomersmulticentreregistry
AT loforteantonio fiveyearoutcomeaftercontinuousflowlvadwithfullmagneticheartmate3versushybridlevitationsystemheartwareapropensityscorematchedstudyfromanallcomersmulticentreregistry
AT attisanimatteo fiveyearoutcomeaftercontinuousflowlvadwithfullmagneticheartmate3versushybridlevitationsystemheartwareapropensityscorematchedstudyfromanallcomersmulticentreregistry
AT maianimassimo fiveyearoutcomeaftercontinuousflowlvadwithfullmagneticheartmate3versushybridlevitationsystemheartwareapropensityscorematchedstudyfromanallcomersmulticentreregistry
AT iacovoniattilio fiveyearoutcomeaftercontinuousflowlvadwithfullmagneticheartmate3versushybridlevitationsystemheartwareapropensityscorematchedstudyfromanallcomersmulticentreregistry
AT nisiteodora fiveyearoutcomeaftercontinuousflowlvadwithfullmagneticheartmate3versushybridlevitationsystemheartwareapropensityscorematchedstudyfromanallcomersmulticentreregistry
AT comissomarina fiveyearoutcomeaftercontinuousflowlvadwithfullmagneticheartmate3versushybridlevitationsystemheartwareapropensityscorematchedstudyfromanallcomersmulticentreregistry
AT terziamedeo fiveyearoutcomeaftercontinuousflowlvadwithfullmagneticheartmate3versushybridlevitationsystemheartwareapropensityscorematchedstudyfromanallcomersmulticentreregistry
AT debonismichele fiveyearoutcomeaftercontinuousflowlvadwithfullmagneticheartmate3versushybridlevitationsystemheartwareapropensityscorematchedstudyfromanallcomersmulticentreregistry
AT vendraminigor fiveyearoutcomeaftercontinuousflowlvadwithfullmagneticheartmate3versushybridlevitationsystemheartwareapropensityscorematchedstudyfromanallcomersmulticentreregistry
AT boffinimassimo fiveyearoutcomeaftercontinuousflowlvadwithfullmagneticheartmate3versushybridlevitationsystemheartwareapropensityscorematchedstudyfromanallcomersmulticentreregistry
AT musumecifrancesco fiveyearoutcomeaftercontinuousflowlvadwithfullmagneticheartmate3versushybridlevitationsystemheartwareapropensityscorematchedstudyfromanallcomersmulticentreregistry
AT lucianigiovannibattista fiveyearoutcomeaftercontinuousflowlvadwithfullmagneticheartmate3versushybridlevitationsystemheartwareapropensityscorematchedstudyfromanallcomersmulticentreregistry
AT rinaldimauro fiveyearoutcomeaftercontinuousflowlvadwithfullmagneticheartmate3versushybridlevitationsystemheartwareapropensityscorematchedstudyfromanallcomersmulticentreregistry
AT pacinidavide fiveyearoutcomeaftercontinuousflowlvadwithfullmagneticheartmate3versushybridlevitationsystemheartwareapropensityscorematchedstudyfromanallcomersmulticentreregistry
AT onoratifrancesco fiveyearoutcomeaftercontinuousflowlvadwithfullmagneticheartmate3versushybridlevitationsystemheartwareapropensityscorematchedstudyfromanallcomersmulticentreregistry